MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ana.78002

Медицинская библиотека · Annals of neurology · 2025

Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.

Abdelmoity Omar, Wisch Julie K, Kennedy James T, Goyal Manu, Vlassenko Andrei, Flores Shaney, Handen Benjamin L, Head Elizabeth, Keator David, Rafii Michael S, Lao Patrick, Lai Florence, Rosas H Diana, Hartley Sigan L, Zaman Shahid, Brickman Adam M, Tudorascu Dana, Lee Joseph H, Allegri Ricardo Francisco, Keefe Sarah, la Fougere Christian, Llibre-Guerra Jorge, Ikeuchi Takeshi, Morris John C, Roh Jee Hoon, Day Gregory S, Levin Johannes, Schofield Peter R, Gordon Brian A, Benzinger Tammie L S, Ances Beau M, Alzheimer's Biomarker Consortium‐Down Syndrome and the Dominantly Inherited Alzheimer Network

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

OBJECTIVES

Directly compare the brain glucose patterns seen with [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD).

METHODS

Cross-sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within-group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses.

RESULTS

Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls (p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls (p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive.

INTERPRETATION: Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG-PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237-1248.

Для цитирования: Abdelmoity Omar, Wisch Julie K, Kennedy James T, Goyal Manu, Vlassenko Andrei, Flores Shaney, Handen Benjamin L, Head Elizabeth, Keator David, Rafii Michael S, Lao Patrick, Lai Florence, Rosas H Diana, Hartley Sigan L, Zaman Shahid, Brickman Adam M, Tudorascu Dana, Lee Joseph H, Allegri Ricardo Francisco, Keefe Sarah, la Fougere Christian, Llibre-Guerra Jorge, Ikeuchi Takeshi, Morris John C, Roh Jee Hoon, Day Gregory S, Levin Johannes, Schofield Peter R, Gordon Brian A, Benzinger Tammie L S, Ances Beau M, Alzheimer's Biomarker Consortium‐Down Syndrome and the Dominantly Inherited Alzheimer Network. Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.. Annals of neurology. 2025. DOI: 10.1002/ana.78002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.